Systematic, iterative HSV-based viral immunotherapy discovery platform leveraging human biology, computational biology, and advanced analytics to create new viral immunotherapy candidates for solid tumors. Generates both replication-defective and replication-competent agents. Multiple preclinical candidates include Alpha-201 Macro1 (CD47/SIRPα), a TLS-inducing multimodal immunotherapy, and an IL-12/IL-15 encoding candidate.

Targets: IL-12, IL-15, CD47, SIRPα

enLIGHTEN Discovery Platform · University of Pennsylvania

Systematic, iterative herpes simplex virus-based platform leveraging human biology and advanced analytics; focus area: novel viral immunotherapies for cancer

enLIGHTEN

Systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create multimodal biological immunotherapies for solid tumors; deconvolutes tumor microenvironment characteristics and translates them into optimized multi-gene payloads for specific indications.

Adenovirus viral immunotherapy platform

Off-the-shelf engineered adenovirus platform for intratumoral administration designed to induce immunogenic cell death and systemic anti-tumor immune response; focus area: solid tumors / oncology

HSV viral immunotherapy platform · MGB

Off-the-shelf engineered herpes simplex virus (HSV) platform for intratumoral administration; includes rQNestin (oncolytic HSV) licensed from MGB; focus area: solid tumors / oncology

rQNestin · MGB

Genetically modified oncolytic herpes simplex virus platform licensed from MGB; being developed for treatment of certain types of cancers

enLIGHTEN Discovery

Discovery platform generating novel oncolytic and immunotherapy candidates targeting solid tumors; specific candidates not yet named.

Discontinued (1)

aglatimagene besadenovec — Pancreatic Ductal Adenocarcinoma · paused further clinical development in October 2025 in context of portfolio prioritization unless externally funded